高级搜索
赵冲, 汪强, 武奋萍, 刘胜兰. LncRNA AC010145.4与小细胞肺癌预后及化疗耐药的关系[J]. 肿瘤防治研究, 2017, 44(10): 677-681. DOI: 10.3971/j.issn.1000-8578.2017.17.0504
引用本文: 赵冲, 汪强, 武奋萍, 刘胜兰. LncRNA AC010145.4与小细胞肺癌预后及化疗耐药的关系[J]. 肿瘤防治研究, 2017, 44(10): 677-681. DOI: 10.3971/j.issn.1000-8578.2017.17.0504
ZHAO Chong, WANG Qiang, WU Fenping, LIU Shenglan. Relationship of LncRNA AC010145.4 Expression with Prognosis and Chemoresistance of Small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 677-681. DOI: 10.3971/j.issn.1000-8578.2017.17.0504
Citation: ZHAO Chong, WANG Qiang, WU Fenping, LIU Shenglan. Relationship of LncRNA AC010145.4 Expression with Prognosis and Chemoresistance of Small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 677-681. DOI: 10.3971/j.issn.1000-8578.2017.17.0504

LncRNA AC010145.4与小细胞肺癌预后及化疗耐药的关系

Relationship of LncRNA AC010145.4 Expression with Prognosis and Chemoresistance of Small Cell Lung Cancer

  • 摘要:
    目的 探讨LncRNA AC010145.4在小细胞肺癌患者组织中的表达及其与患者化疗敏感度和预后的关系。
    方法 应用实时荧光定量PCR法检测67例SCLC、27例癌旁及40例正常肺组织中LncRNA AC010145.4的表达,采用χ2检验分析LncRNA AC010145.4表达与SCLC患者临床病理特征的关系,Kaplan-Meier法分析LncRNA AC010145.4表达与SCLC患者生存时间的关系,单因素及多因素分析影响SCLC预后的因素。
    结果 SCLC组织中LncRNA AC010145.4的表达水平明显高于癌旁组织及正常肺组织(均P < 0.001)。LncRNA AC010145.4在化疗耐药患者中的表达明显高于化疗敏感者(P < 0.05);LncRNA AC010145.4表达与SCLC患者的性别、年龄无关,而与疾病分期、淋巴结转移、远处转移、化疗耐药相关(均P < 0.05)。高表达LncRNA AC010145.4患者的总生存时间及无进展生存时间均短于低表达者(均P < 0.001)。单因素及多因素分析发现LncRNA AC010145.4表达、疾病分期、远处转移是SCLC患者独立的预后因素(均P < 0.05)。
    结论 LncRNA AC010145.4参与调节SCLC的发生和发展,可能是潜在的SCLC患者预后评估的生物标志物。

     

    Abstract:
    Objective To investigate the expression of long non-coding RNA AC010145.4 (LncRNA AC010145.4) and its relationship with prognosis and chemoresistance of small cell lung cancer (SCLC) patients.
    Methods The expression of LncRNA AC010145.4 in 67 cases of SCLC tissues, 27 cases of para-cancerous tissues and 40 cases of normal lung tissues were detected by real-time fluorescent quantitative PCR. The relationship of LncRNA AC010145.4 expression with clinicopathological characteristics was analysed by χ2 test. The relationship between AC010145.4 expression and survival time of SCLC patients were analyzed by Kaplan-Meier analysis. Univariate and multivariate analysis were used to analyze prognosis factor of SCLC.
    Results The expression level of LncRNA AC010145.4 in SCLC tissues was higher than those in para-cancerous tissues and normal lung tissues (all P < 0.001). The expression of LncRNA AC010145.4 was significantly higher in chemoresistance patients than that in chemosensitive patients (P < 0.05). LncRNA AC010145.4 expression was positively correlated with disease stage, lymph node metastasis, distant metastasis, chemosensitivity (all P < 0.05). The overall survival time and progression-free survival time of the patients with high LncRNA AC010145.4 expression were shorter than those with low LncRNA AC010145.4 expression (all P < 0.001). LncRNA AC010145.4 expression, disease stage and distant metastasis were independent prognostic factors (all P < 0.05).
    Conclusion LncRNA AC010145.4 is involved in the occurrence and development of SCLC, and may be used as a molecular marker for the prognosis evaluation of SCLC patients.

     

/

返回文章
返回